Teva Vascepa ANDA Is ‘Discontinued’ Despite Settlement Agreement
Amarin CEO Speculates On New Status
Executive Summary
Teva was in position to introduce further generic competition to Amarin’s Vascepa following legal setbacks for the originator. However, the firm’s ANDA has since been listed as discontinued.
You may also be interested in...
Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.
Hikma Raises Expectations For 2021 After A Host Of Launches
On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.
Dr Reddy’s Accuses Amarin Of ‘Illegally’ Blocking Vascepa API Supply
Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.